 JERSEY CITY, N.J., March 29, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter ended on December 31, 2020 and provided an update on recent clinical and corporate developments. 